Literature DB >> 22148985

Severe paramethoxymethamphetamine (PMMA) and paramethoxyamphetamine (PMA) outbreak in Israel.

Yael Lurie1, Asher Gopher, Ophir Lavon, Shlomo Almog, Liron Sulimani, Yedidia Bentur.   

Abstract

CONTEXT: Paramethoxymethamphetamine (PMMA) is a hallucinogenic synthetic substituted amphetamine that was not included in the Israeli Controlled Substance Act (CSA).
OBJECTIVE: To report a severe PMMA and paramethoxyamphetamine (PMA) outbreak. PATIENTS AND METHODS: The Israeli national forensic toxicology laboratory analyzes the body fluids of unnatural deaths by means of screening immunoassays and chromatographic confirmation and quantification. Samples are referred to this laboratory by the Israeli Forensic Medicine Institute and by hospitals following consultation with the Israel Poison Information Center. The forensic toxicology laboratory began determining PMMA and PMA in February 2007. In all fatal cases with a positive immunoassay screen for amphetamines, a chromatographic analysis of PMA and PMMA was performed. The laboratory and demographic data of consecutive patients in whom PMMA or PMA were detected, were collected during 1 year and subjected to descriptive analysis.
RESULTS: Of 108 fatal cases with a positive screen for amphetamines, 32 were confirmed. Twenty-four of the 32 cases tested positive for PMMA and PMA--age 27 ± 5 years, 79.2% males, post mortem whole blood PMMA and PMA concentrations 0.35 ± 0.24 and 2.72 ± 1.67 mcg/mL, respectively. Co-exposures were detected in 17 (70.8%) fatalities; including methylenedioxymethamphetamine, methylenedioxyamphetamine, cocaine, cannabinoids, cathinone derivatives, ephedrine/pseudoephedrine, opiates, and ethanol. In addition, five non-fatal male cases were identified; age 32 ± 5 years, four had co-exposures to cocaine, cathinone derivatives, and cannabinoids. These findings led to the inclusion of PMMA in the CSA in July 2007, resulting in only three more fatalities in the following year. DISCUSSION: We report an outbreak of PMMA and PMA poisoning resulting in 24 fatalities, and the post mortem whole blood and urine concentrations of these two compounds. PMA was probably the result of PMMA metabolism. Stimulant co-exposures may have contributed to the severity of the poisoning.
CONCLUSION: Forensic laboratory and poison center co-operation is important in identifying a new drug of abuse.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22148985     DOI: 10.3109/15563650.2011.635148

Source DB:  PubMed          Journal:  Clin Toxicol (Phila)        ISSN: 1556-3650            Impact factor:   4.467


  4 in total

1.  Deaths from exposure to paramethoxymethamphetamine in Alberta and British Columbia, Canada: a case series.

Authors:  Jennifer J E Nicol; Mark C Yarema; Graham R Jones; Walter Martz; Roy A Purssell; Judy C MacDonald; Ian Wishart; Monica Durigon; Despina Tzemis; Jane A Buxton
Journal:  CMAJ Open       Date:  2015-01-13

2.  Effects of MDMA on body temperature in humans.

Authors:  Matthias E Liechti
Journal:  Temperature (Austin)       Date:  2014-10-31

3.  Investigation of Biotransformation Products of p-Methoxymethylamphetamine and Dihydromephedrone in Wastewater by High-Resolution Mass Spectrometry.

Authors:  Juliet Kinyua; Aikaterini K Psoma; Nikolaos I Rousis; Maria-Christina Nika; Adrian Covaci; Alexander L N van Nuijs; Νikolaos S Τhomaidis
Journal:  Metabolites       Date:  2021-01-25

4.  Effect of Some Psychoactive Drugs Used as 'Legal Highs' on Brain Neurotransmitters.

Authors:  Krystyna Gołembiowska; Alexandra Jurczak; Katarzyna Kamińska; Karolina Noworyta-Sokołowska; Anna Górska
Journal:  Neurotox Res       Date:  2015-10-26       Impact factor: 3.911

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.